Application of adipose-derived stem cells in treating fibrosis  

作　　者：Zhu-Jun Li Li-Quan Wang Yun-Zhu Li Chen-Yu Wang Jiu-Zuo Huang Nan-Ze Yu Xiao Long 

机构地区：[1]Department of Plastic and Reconstructive Surgery,Peking Union Medical College Hospital of Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing 100730,China

出　　处：《World Journal of Stem Cells》2021年第11期1747-1761,共15页世界干细胞杂志（英文版）（电子版）

基　　金：Supported by the National Natural Science Foundation of China,No.81670444;and the CAMS Innovation Fund for Medical Sciences(CIFMS),No.2020-I2MC&T-A-004.

摘　　要：Fibrosis is the hyperactivation of fibroblasts that results in excessive accumulation of extracellular matrix,which is involved in numerous pathological changes and diseases.Adipose-derived stem cells(ASCs)are promising seed cells for regenerative medicine due to their bountiful source,low immunogenicity and lack of ethical issues.Their anti-fibrosis,immunomodulation,angiogenesis and other therapeutic effects have made them suitable for treating fibrosis-related diseases.Here,we review the literature on ASCs treating fibrosis,elaborate and discuss their mechanisms of action,changes in disease environment,ways to enhance therapeutic effects,as well as current preclinical and clinical studies,in order to provide a general picture of ASCs treating fibrotic diseases.

关 键 词：Adipose-derived stem cells FIBROSIS IMMUNOMODULATION MODIFICATION Therapeutic effect Clinical trials 

分 类 号：R575.2[医药卫生—消化系统]